PLGA Nanoparticles – Bridging the Gap from R&D to GMP
By Fortis Life SciencesWhile the bulk polymer PLGA is approved by both the Food and Drug Administration (FDA) and European Medicine Agency (EMA) and is listed in the US Pharmacopoeia (USP) as a pharmaceutical excipient, there are few examples taking advantage of the unique polymer properties for use in nanomedicine applications.
Recent research and development efforts have focused on changing this, however, using PLGA not just as an inactive material but as an integral component of nanoparticle formulations that enable a wide range of nanomedicine applications, including drug targeting and delivery, imaging, immunoassays and medical devices.
To read more, please download this free white paper.